<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01796665</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-12-005</org_study_id>
    <nct_id>NCT01796665</nct_id>
  </id_info>
  <brief_title>A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd. Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel (Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5%), and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Padagis LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the efficacy and safety of Perrigo's test&#xD;
      formulation of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% compared to&#xD;
      the already marketed formulation, Acanya gel in patients with acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change in the Inflammatory (Papules and Pustules) Lesion Count</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Per protocol population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Count</measure>
    <time_frame>Baseline to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Success on Investigator's Global Evaluation</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Percentage of subjects with a clinical response of &quot;success&quot;, defined as an IGA score that is at least 2 grades less than the baseline assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1180</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acanya Gel applied to the affected areas of the face once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of the Test product applied to the affected areas of the face once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%</intervention_name>
    <arm_group_label>Test product</arm_group_label>
    <other_name>Test product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acanya Gel</intervention_name>
    <arm_group_label>Reference product</arm_group_label>
    <other_name>Reference product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product</intervention_name>
    <arm_group_label>Placebo product</arm_group_label>
    <other_name>Placebo product</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject and/or parent or legally authorized representative must sign an Institutional&#xD;
             Review Board (IRB) approved written informed consent/assent.&#xD;
&#xD;
          2. Male or female, 12 to 40 years of age, inclusive.&#xD;
&#xD;
          3. Definite clinical diagnosis of facial acne vulgaris with an inflammatory lesion&#xD;
             (papules and pustules) count between 20 and 50 and a non-inflammatory (open and closed&#xD;
             comedones) lesion count between 25 and 100 and no more than 2 nodulocystic lesions&#xD;
             (i.e., nodules and cysts) including those present on the nose.&#xD;
&#xD;
          4. Baseline Investigator's Global Assessment Score of 3 (moderate severity) or 4 (severe)&#xD;
             on a severity scale of 0 to 4.&#xD;
&#xD;
          5. Willing and able to understand and comply with the requirements of the study, apply&#xD;
             the medication as instructed, refrain from use of all other topical acne medication or&#xD;
             topical antibiotics during the 12-week treatment period, return for the required&#xD;
             treatment period visits, comply with therapy prohibitions, and are able to complete&#xD;
             the study.&#xD;
&#xD;
          6. In general good health and free from any clinically significant disease, other than&#xD;
             acne vulgaris, that might interfere with the study evaluations.&#xD;
&#xD;
          7. Females of childbearing potential (excluding women who are surgically sterilized or&#xD;
             post menopausal for at least 2 years), in addition to having a negative urine&#xD;
             pregnancy test, must be willing to use an acceptable form of birth control during the&#xD;
             study. For the purpose of this study, the following are considered acceptable methods&#xD;
             of birth control: Oral Contraceptives, Contraceptive patches, Contraceptive Injection&#xD;
             (Depo-Provera), Contraceptive Implant (Implanon), Vaginal Contraceptive (Nuva-Ring),&#xD;
             IUD, hormonal IUD (Mirena); double-barrier methods (e.g. condom and spermicide) and&#xD;
             abstinence with a documented second acceptable method of birth control should subject&#xD;
             become sexually active. A sterile sexual partner is not considered an adequate form of&#xD;
             birth control. Subjects entering the trial that are on hormonal contraceptives must&#xD;
             have been on this method for at least 3 months (90 days) prior to the trial and&#xD;
             continue the method for the duration of the trial. Subjects who had used hormonal&#xD;
             contraception and stopped must have stopped no less than 3 months (90 days) prior to&#xD;
             baseline.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, breast feeding, or planning a pregnancy within the study participation&#xD;
             period.&#xD;
&#xD;
          2. More than 2 facial nodulocystic lesions (i.e. nodules and cysts).&#xD;
&#xD;
          3. Acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne,&#xD;
             etc.).&#xD;
&#xD;
          4. Active cystic acne or Polycystic Ovarian Syndrome.&#xD;
&#xD;
          5. History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or&#xD;
             antibiotic-associated colitis.&#xD;
&#xD;
          6. Use of neuromuscular blocking agents (nondepolarizing agents and depolarizing agents)&#xD;
&#xD;
          7. Any other facial skin condition that might interfere with acne vulgaris diagnosis&#xD;
             and/or assessment (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell&#xD;
             carcinoma, eczema, acneform eruptions caused by medications, steroid acne, steroid&#xD;
             folliculitis, or bacterial folliculitis).&#xD;
&#xD;
          8. Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere&#xD;
             with diagnosis or assessment of acne vulgaris.&#xD;
&#xD;
          9. History of unresponsiveness to topical Clindamycin Phosphate and/or benzoyl peroxide&#xD;
             therapy.&#xD;
&#xD;
         10. Use of systemic Clindamycin products 4 weeks prior to baseline or throughout the&#xD;
             study.&#xD;
&#xD;
         11. History of hypersensitivity or allergy to Clindamycin Phosphate, benzoyl peroxide&#xD;
             and/or any ingredient in the study medication.&#xD;
&#xD;
         12. Use within 6 months prior to baseline or during the study of oral retinoids (e.g.&#xD;
             Accutane®) or therapeutic vitamin A supplements of greater than 10,000 units/day&#xD;
             (multivitamins are allowed).&#xD;
&#xD;
         13. Use within 30 days prior to baseline or during the study of therapeutic vitamin D&#xD;
             supplement (daily multivitamins with total 800IU Vitamin D are allowed).&#xD;
&#xD;
         14. Use of medications known to exacerbate acne (Vitamin B12, lithium, corticosteroids;&#xD;
             Vitamin B12, etc as part of a multivitamin regimen is allowed).&#xD;
&#xD;
         15. Start or change of dose of hormonal treatment (oral, implanted, topical contraceptives&#xD;
             and androgens) 3 months prior to base-line or throughout the study. Use of such&#xD;
             therapy must remain constant during the study.&#xD;
&#xD;
         16. Use of medicated make-up throughout the study and significant change in the use of&#xD;
             consumer products within 30 days of study entry and throughout the study (other than&#xD;
             study supplied cleanser and lotion).&#xD;
&#xD;
         17. Use within 30 days prior to baseline or during the study of 1) systemic steroids*, 2)&#xD;
             systemic (e.g., oral or injectable) antibiotics, 3) systemic treatment for acne&#xD;
             vulgaris (other than oral retinoids which require a 6-month washout), or 4) systemic&#xD;
             anti-inflammatory or immunosuppressive agents**. (*Intranasal and inhaled&#xD;
             corticosteroids do not require a washout and may be used throughout the study if at a&#xD;
             stable and standard dose.)**Subjects may use Acetaminophen for pain relief, as needed&#xD;
             throughout the study).&#xD;
&#xD;
         18. Use within 14 days prior to baseline or during the study of 1) topical steroids, 2)&#xD;
             topical retinoids, 3) topical anti-acne medications (e.g. Benzoyl peroxide, retinoids,&#xD;
             azelaic acid, α-hydroxy/glycolic acid, Clindamycin, etc.) including OTC preparations&#xD;
             4) benzoyl peroxide, 5) topical anti-inflammatory agents, or 6) topical antibiotics.&#xD;
&#xD;
         19. Use on the face within 30 days prior to baseline or during the study of 1)&#xD;
             cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne&#xD;
             surgery, 5) intralesional steroids, or 6) x-ray therapy.&#xD;
&#xD;
         20. Use of medicated cleansers (e.g. benzoyl peroxide, salicylic acid, sulfur or&#xD;
             triclosan) within 2 weeks of study start and throughout the study.&#xD;
&#xD;
         21. Subject consumes excessive alcohol, abuses drugs, or has a condition that could&#xD;
             compromise the subject's ability to comply with study requirements.&#xD;
&#xD;
         22. Use of Spironolactone for 4 weeks prior to baseline visit and throughout the study&#xD;
             period is prohibited.&#xD;
&#xD;
         23. Use of Antipruritics, including antihistamines within 24 hours of all study visits&#xD;
             (Visit 1 through Visit 4).&#xD;
&#xD;
         24. Participation in any clinical study involving an investigational product or device in&#xD;
             the 4 weeks prior to study entry or throughout the study.&#xD;
&#xD;
         25. Previous enrollment in this current study.&#xD;
&#xD;
         26. Use of tanning booths, sun lamps, sunbathing or excessive exposure to the sun 1 week&#xD;
             prior to enrollment and throughout the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 18, 2013</study_first_submitted>
  <study_first_submitted_qc>February 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2013</study_first_posted>
  <results_first_submitted>November 24, 2020</results_first_submitted>
  <results_first_submitted_qc>December 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 20, 2021</results_first_posted>
  <disposition_first_submitted>September 23, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>September 23, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 1, 2013</disposition_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 9, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT01796665/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 9, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT01796665/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.&#xD;
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>Acanya Gel applied to the affected areas of the face once daily.&#xD;
Acanya Gel</description>
        </group>
        <group group_id="P3">
          <title>Placebo Product</title>
          <description>Placebo of the Test product applied to the affected areas of the face once daily.&#xD;
Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="474"/>
                <participants group_id="P2" count="469"/>
                <participants group_id="P3" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="416"/>
                <participants group_id="P2" count="396"/>
                <participants group_id="P3" count="195"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.&#xD;
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>Acanya Gel applied to the affected areas of the face once daily.&#xD;
Acanya Gel</description>
        </group>
        <group group_id="B3">
          <title>Placebo Product</title>
          <description>Placebo of the Test product applied to the affected areas of the face once daily.&#xD;
Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="474"/>
            <count group_id="B2" value="469"/>
            <count group_id="B3" value="237"/>
            <count group_id="B4" value="1180"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.7" spread="6.6"/>
                    <measurement group_id="B2" value="19.9" spread="6.37"/>
                    <measurement group_id="B3" value="19.8" spread="6.23"/>
                    <measurement group_id="B4" value="19.8" spread="6.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="257"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="661"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="212"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="374"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="328"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="156"/>
                    <measurement group_id="B4" value="806"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="289"/>
                    <measurement group_id="B2" value="304"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="746"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in the Inflammatory (Papules and Pustules) Lesion Count</title>
        <description>Per protocol population</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.&#xD;
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Acanya Gel applied to the affected areas of the face once daily.&#xD;
Acanya Gel</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>Placebo of the Test product applied to the affected areas of the face once daily.&#xD;
Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in the Inflammatory (Papules and Pustules) Lesion Count</title>
          <description>Per protocol population</description>
          <population>Per protocol population</population>
          <units>percent change of lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="339"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.70" spread="34.55"/>
                    <measurement group_id="O2" value="63.89" spread="39.21"/>
                    <measurement group_id="O3" value="42.22" spread="43.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>96.57</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.5</ci_lower_limit>
            <ci_upper_limit>105.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Count</title>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.&#xD;
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Acanya Gel applied to the affected areas of the face once daily.&#xD;
Acanya Gel</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>Placebo of the Test product applied to the affected areas of the face once daily.&#xD;
Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion Count</title>
          <population>Per protocol population</population>
          <units>percent change of lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="339"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.57" spread="31.79"/>
                    <measurement group_id="O2" value="51.59" spread="39.85"/>
                    <measurement group_id="O3" value="33.33" spread="36.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>99.96</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.9</ci_lower_limit>
            <ci_upper_limit>110.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success on Investigator's Global Evaluation</title>
        <description>Percentage of subjects with a clinical response of &quot;success&quot;, defined as an IGA score that is at least 2 grades less than the baseline assessment.</description>
        <time_frame>Baseline to week 12</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.&#xD;
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Acanya Gel applied to the affected areas of the face once daily.&#xD;
Acanya Gel</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>Placebo of the Test product applied to the affected areas of the face once daily.&#xD;
Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success on Investigator's Global Evaluation</title>
          <description>Percentage of subjects with a clinical response of &quot;success&quot;, defined as an IGA score that is at least 2 grades less than the baseline assessment.</description>
          <population>Per protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="365"/>
                <count group_id="O2" value="339"/>
                <count group_id="O3" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>-1.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.23</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>84 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% applied to the affected areas of the face once daily.&#xD;
Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>Acanya Gel applied to the affected areas of the face once daily.&#xD;
Acanya Gel</description>
        </group>
        <group group_id="E3">
          <title>Placebo Product</title>
          <description>Placebo of the Test product applied to the affected areas of the face once daily.&#xD;
Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Skull Fracture, Brain Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective Disorder, Attention Deficit/Hyperactivity Disorder, and Oppositional Defiant Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="474"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="474"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="469"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schwartz</name_or_title>
      <organization>Perrigo</organization>
      <phone>718-960-9900</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

